01 / DESIGN
What was studied?
An exploratory extension followed 327 participants from STEP 1 for a year after both study treatment and lifestyle intervention ended.
02 / FINDINGS
What did the researchers report?
Participants previously assigned semaglutide regained about two-thirds of their earlier weight loss on average. Many cardiometabolic measurements moved back toward their starting values.
03 / LIMITS
How should it be interpreted?
The extension involved a subset of the original trial and was exploratory. Because drug treatment and lifestyle support stopped together, it cannot fully isolate their separate effects. It does not prescribe a treatment plan.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.